TITLE

Varenicline for smoking cessation: Is it a heartbreaker?

AUTHOR(S)
Hays, J. Taylor
PUB. DATE
September 2011
SOURCE
CMAJ: Canadian Medical Association Journal;9/6/2011, Vol. 183 Issue 12, p1346
SOURCE TYPE
Academic Journal
DOC. TYPE
Opinion
ABSTRACT
The author discusses the paper of S. Singh and colleagues entitled "Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis." The author states that a meta-analysis which evaluated adverse cardiovascular events' risk linked with varenicline use to stop smoking is presented in the paper. The author adds that clinicians are being urged by S. Singh and colleagues to cautiously balance the benefits and risks of varenicline.
ACCESSION #
65922944

 

Related Articles

  • Smokers Using Varenicline to Quit the Habit at Greater Risk of Heart Attack Or Other Serious Heart Problems.  // Biomedical Market Newsletter;7/14/2011, p294 

    The article focuses on the study conducted by Sonal Singh of John Hopkins University School of Medicine regarding the risks offered by varenicline for smokers who want to quit smoking. It states that based from the study, the use of varenicline offered 72% increased risk of a major harmful...

  • Milk: Getting to the heart of it.  // Irish Farmers Monthly;Jan2011, p48 

    The article focuses on the meta-analysis which examined the association of milk with the risk of total mortality and cardiovascular disease (CVD), in which the results showed that milk has an inverse relationship with CVD risk, while, mortality and coronary heart disease (CHD) showed no connection.

  • Varenicline: quantifying the risk. Blankfield, Robert P.; Takagi, Hisato; Umemoto, Takuya; Woods, David J.; Caswell, Mark D.; Squire, Edward N.; Alper, Brian S.; Singh, Sonal; Loke, Yoon K.; Spangler, John G.; Furberg, Curt D. // CMAJ: Canadian Medical Association Journal;9/6/2011, Vol. 183 Issue 12, p1404 

    Several letters to the editor are presented in response to the article "Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis," by Sonal Singh and colleagues, as well as a response to the said letters to the editor.

  • Varenicline: cardiovascular safety. Samuels, Larry; Singh, Sonal; Loke, Yoon K.; Spangler, John G.; Furberg, Curt D. // CMAJ: Canadian Medical Association Journal;9/6/2011, Vol. 183 Issue 12, p1407 

    A letter to the editor and a reply are presented in response to the article"Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis," by Sonal Singh and colleagues.

  • Chantix Associated with 72% Increased Risk of Serious CV Events.  // Biomedical Market Newsletter;7/14/2011, p293 

    The article reports on a study which revealed the health risk of varenicline use. According to the findings of the study, the use of varenicline, which is sold with the brand name ChantixTM by Pfizer, is linked to a 72% increased hospitalization risk because of an adverse cardiovascular (CV)...

  • Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. Chakravarthy, Usha; Wong, Tien Y.; Fletcher, Astrid; Piault, Elisabeth; Evans, Christopher; Zlateva, Gergana; Buggage, Ronald; Pleil, Andreas; Mitchell, Paul // BMC Ophthalmology;2010, Vol. 10, p31 

    Background: Age-related macular degeneration (AMD) is the leading cause of blindness in Western countries. Numerous risk factors have been reported but the evidence and strength of association is variable. We aimed to identify those risk factors with strong levels of evidence which could be...

  • Physicians' Appraisal and Response to Early Evidence on Cardiovascular Risk Associated with Rosiglitazone: Knowledge Translation in Clinical Practice. Brown, Garielle E.; Lewin, Adriane M.; De Souza, Michael A.; Edwards, Alun L.; Ghali, William A.; Rabi, Doreen M. // Canadian Journal of General Internal Medicine;2014, Vol. 9 Issue 1, p11 

    In 2007, a high-profile meta-analysis raised concerns about the safety of rosiglitazone, a thenpopular oral hypoglycemic agent. In this study, the authors describe how physicians accessed, evaluated, and applied this information clinically. Their findings showed that although a highly publicized...

  • Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk. Jafri, Haseeb; Alsheikh-Ali, Alawi A.; Karas, Richard H. // Annals of Internal Medicine;12/21/2010, Vol. 153 Issue 12, p800 

    Background: Low levels of high-density lipoprotein cholesterol (HDL-C) are associated with an increased risk for myocardial infarction (MI). Although statins reduce the risk for MI, most cardiovascular events still occur despite statin treatment. Purpose: Using meta-analysis of large randomized,...

  • 2014 - Pooled RCTs: BP-lowering drugs reduced major CV events; absolute reductions were greater with higher baseline risk. Burden, A. C. Felix // ACP Journal Club;12/1/2014, Vol. 161 Issue 12, p1 

    The article discusses the randomized controlled study conducted to examine the effectiveness of blood pressure-lowering treatment based on cardiovascular (CV) risk and reducing the CV mortality. Topics discussed include factors responsible for CV diseases including body mass index, smoking...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics